PRCT vs NVS

For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.

2% revenue growth year-over-year, versus 6. 0% for Novartis AG (NVS). Novartis AG (NVS) offers the better valuation at 20. 6x trailing P/E (16. 9x forward), making it the more compelling value choice. Analysts rate PROCEPT BioRobotics Corporation (PRCT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +99.

3%, compared to -40. 9% for PROCEPT BioRobotics Corporation (PRCT). Over 10 years, the gap is even starker: NVS returned +188. 8% versus PRCT's -40. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus PROCEPT BioRobotics Corporation's 1. 23β — meaning PRCT is approximately 191% more volatile than NVS relative to the S&P 500. On balance sheet safety, PROCEPT BioRobotics Corporation (PRCT) carries a lower debt/equity ratio of 14% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.

2% versus 6. 0% for Novartis AG (NVS). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to 1. 7% for PROCEPT BioRobotics Corporation. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus -31. 0% for PROCEPT BioRobotics Corporation — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -33. 7% for PRCT. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRCT: 79.

4% to $44. 50.

In this comparison, NVS (2.

7% yield) pays a dividend. PRCT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 7% yield, +188. 8% 10Y return). Both have compounded well over 10 years (NVS: +188. 8%, PRCT: -40. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRCT is a small-cap high-growth stock; NVS is a large-cap quality compounder stock. NVS pays a dividend while PRCT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.